

Date: May 22, 2024

## Change Notification

Dear Valued Customer,

The purpose of this notification is to inform you of a change in the Master Cell Bank (MCB) and Working Cell Bank (WCB) used in the production of iMatrix-511MG

### Affected Product(s)

Product number	Product Description
892 005	iMatrix-511 MG (175 µg x6), 1,050 µg

### This change notification is related to

MCB/WCB for production of laminin-511 E8 fragment protein (iMatrix-511MG)

### Change Details

- The cell line will be changed to the same cell line used for the production of iMatrix-511 (892 011/012) that we currently sell for research purposes. iMatrix-511 cell line has been changed since May 2022, and no performance differences have been reported between the previous and current cell lines.
- The host cell for the laminin 511 E8 fragment protein remains unchanged: it is still CHO-S cells.
- There is no change in the amino acid sequence of the product.
- The test items and specifications in the Certificate of Analysis (CoA) remain the same.
- No difference was observed in integrin binding activity or verification using iPS cells before and after the cell line change.
- The product after the change has obtained a "Certificate of Eligibility for Regenerative Medical Product Material" from PMDA (Pharmaceuticals and Medical Devices Agency).

### Implementation Date/Lot Number

Starting from Lot No. MG24C501, shipments are scheduled for June 2024.

### Contact Information

If you require samples of the product after the change or need further information, please contact our distributor, Matrixome, Inc., at the following web site: <https://matrixome.co.jp/en/contact>